|
|
||||||||
1 Division of Hematology and Oncology, Department of Internal Medicine and 2 Pathology, University of Michigan, Ann Arbor, Michigan 48109-5669
Prekallikrein (PK) activation on human umbilical endothelial cells (HUVEC) presumably leads to bradykinin liberation. On HUVEC, PK activation requires the presence of cell-bound high-molecular-weight kininogen (HK) and Zn2+. We examined the Zn2+ requirement for HK binding to and the consequences of PK activation on endothelial cells. Optimal HK binding (14 pmol/106 HUVEC) is seen with no added Zn2+ in HEPES-Tyrode buffer containing gelatin versus 16-32 µM added Zn2+ in the same buffer containing bovine serum albumin. The affinity and number of HK binding sites on HUVEC are a dissociation constant of 9.6 ± 1.8 nM and a maximal binding of 1.08 ± 0.26 × 107 sites/cell (means ± SD). PK is activated to kallikrein by an antipain-sensitive mechanism in the presence of HK and Zn2+ on HUVEC, human microvascular endothelial cells, umbilical artery smooth muscle cells, and bovine pulmonary artery endothelial cells. Simultaneous with kallikrein formation, bradykinin (5.0 or 10.3 pmol/106 HUVEC in the absence or presence of lisinopril, respectively) is liberated from cell-bound HK. Liberated bradykinin stimulates the endothelial cell bradykinin B2 receptor to form nitric oxide. Assembly and activation of PK on endothelial cells modulates their physiological activities.
kininogen; prekallikrein; kallikrein; nitric oxide; zinc
This article has been cited by other articles:
![]() |
Y. Wu, V. Rizzo, Y. Liu, I. M. Sainz, N. G. Schmuckler, and R. W. Colman Kininostatin Associates With Membrane Rafts and Inhibits {alpha}v{beta}3 Integrin Activation in Human Umbilical Vein Endothelial Cells Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 1968 - 1975. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Shariat-Madar, F. Mahdi, M. Warnock, J. W. Homeister, S. Srikanth, Y. Krijanovski, L. J. Murphey, A. A. Jaffa, and A. H. Schmaier Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin Blood, July 1, 2006; 108(1): 192 - 199. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Shariat-Madar, E. Rahimy, F. Mahdi, and A. H. Schmaier Overexpression of prolylcarboxypeptidase enhances plasma prekallikrein activation on Chinese hamster ovary cells Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2697 - H2703. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. Fernando, L. P. Fernando, Y. Fukuda, and A. P. Kaplan Assembly, activation, and signaling by kinin-forming proteins on human vascular smooth muscle cells Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H251 - H257. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Shariat-Madar, F. Mahdi, and A. H. Schmaier Recombinant prolylcarboxypeptidase activates plasma prekallikrein Blood, June 15, 2004; 103(12): 4554 - 4561. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Krijanovski, V. Proulle, F. Mahdi, M. Dreyfus, W. Muller-Esterl, and A. H. Schmaier Characterization of molecular defects of Fitzgerald trait and another novel high-molecular-weight kininogen-deficient patient: insights into structural requirements for kininogen expression Blood, June 1, 2003; 101(11): 4430 - 4436. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. R. Baird and P. N. Walsh Factor XI, but Not Prekallikrein, Blocks High Molecular Weight Kininogen Binding to Human Umbilical Vein Endothelial Cells J. Biol. Chem., May 30, 2003; 278(23): 20618 - 20623. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Mahdi, Z. S. Madar, C. D. Figueroa, and A. H. Schmaier Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes Blood, May 15, 2002; 99(10): 3585 - 3596. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |